Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  Phase 3 study of long-term ivacaftor in babies who have a CFTR gating mutation , protocol number Vertex VX-770-126

  This open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of long-term ivacaftor in babies who have a CFTR gating mutation.

  • Age:

    Less than 25 Months

  • Mutation(s):

    One Copy F508del or No Copies F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    18

  • Length of Participation:

    128 weeks

• Anti-InflammatoryEnrolling

  Study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa , protocol number Calithera CX-280-202

  This study will look at the safety and tolerability of CB-280, an oral drug taken twice a day intended to treat infections in the lung and reduce inflammation. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    6

  • Length of Participation:

    2 months

• Anti-InfectiveEnrolling

  Study to evaluate inhaled AP-PA02 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (Armata Phase 1b/2 MAD) , protocol number Armata AP-PA02-101

  This study will look at the safety and tolerability of inhaled AP-PA02, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    60% or greater

  • Number of Visits:

    10

  • Length of Participation:

    31 days

• Nutritional-GIEnrolling

  OPTION 2: Study of AzurRX MS1819 in enteric capsules in adults with cystic fibrosis and exocrine pancreatic insufficiency , protocol number AzurRX AZ-CF2002

  This study will look at the safety and effectiveness of the drug MS1819 in enteric capsules as a pancreatic enzyme replacement therapy (PERT).

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30% or greater

  • Number of Visits:

    10

  • Length of Participation:

    8 weeks

• ObservationalEnrolling

  Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part A) , protocol number BEGIN-OB-19 Part A

  This two-part observational study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.

  • Age:

    Less than 5 Years

  • Mutation(s):

    Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    6

  • Length of Participation:

    3 years

• OtherEnrolling

  SIMPLIFY: Study to evaluate stopping inhaled hypertonic saline or dornase alfa in people with CF who are taking the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor , protocol number SIMPLIFY-IP-19

  This study will test the effects and safety of stopping inhaled hypertonic saline or dornase alfa (Pulmozyme^®) in teens and adults with CF who are also taking the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (Trikafta^®). Trikafta^® is intended to help CFTR function closer to normal, resulting in better clearance of mucus from the lungs. Inhaled hypertonic saline and dornase alfa are intended to thin airway surface liquid and improve clearance of mucus from the lungs. They are considered to be relatively burdensome therapies, so this study will look at the impact of stopping them in people who are also taking Trikafta^®.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    60% or greater

  • Number of Visits:

    4

  • Length of Participation:

    10 weeks

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.